Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

Core Insights - Compass Therapeutics, Inc. announced the acceptance of an abstract for poster presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting scheduled for November 8-10, 2024 [1] - The poster will focus on pharmacodynamic and response biomarkers in a Phase 1 trial of CTX-471, a novel anti-CD137 agonist antibody [2] Company Overview - Compass Therapeutics is a clinical-stage biopharmaceutical company focused on oncology, developing proprietary antibody-based therapeutics for multiple diseases [3] - The company's research emphasizes the interplay between angiogenesis, the immune system, and tumor growth, with a pipeline targeting critical biological pathways for effective antitumor responses [3] - Founded in 2014 and headquartered in Boston, Massachusetts, Compass aims to advance its product candidates through clinical development as standalone therapies and in combination with other proprietary antibodies [3]